REVEAL: CETP Inhibitor Anacetrapib Meets Primary End Point

Anacetrapib significantly reduced major coronary events compared with placebo in patients at risk for cardiac events already receiving a statin in the REVEAL phase 3 study, Merck announced today.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s